Genelux Corporation Common Stock Total Assets
Genelux Corporation Common Stock total assets. Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) holds total assets worth $32.37 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Genelux Corporation Common Stock (GNLX) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Genelux Corporation Common Stock (2019–2025)
Total assets of Genelux Corporation Common Stock from 2019 to 2025. This chart illustrates how Genelux Corporation Common Stock's total assets have evolved over time, based on quarterly financial data. See Genelux Corporation Common Stock share price for real-time trading data and today's change.
Genelux Corporation Common Stock - Asset Composition Analysis
Genelux Corporation Common Stock Total Assets Breakdown (December 2025)
Genelux Corporation Common Stock total assets breakdown as of December 2025. Genelux Corporation Common Stock's total assets of $32.37 Million consist of 79.5% current assets and 20.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Genelux Corporation Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Genelux Corporation Common Stock (GNLX) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genelux Corporation Common Stock's current assets represent 79.5% of total assets in 2025, an increase from 16.8% in 2019.
- Cash Position: Cash and equivalents constituted 28.0% of total assets in 2025, up from 13.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Genelux Corporation Common Stock Competitors by Total Assets
Key competitors of Genelux Corporation Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Genelux Corporation Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.68 | 4.67 | 0.26 |
| Quick Ratio | 3.68 | 4.67 | 0.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $19.48 Million | $28.26 Million | $-4.17 Million |
Genelux Corporation Common Stock - Advanced Valuation Insights
This section examines the relationship between Genelux Corporation Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.08 |
| Latest Market Cap to Assets Ratio | 4.52 |
| Asset Growth Rate (YoY) | -45.2% |
| Total Assets | $19.03 Million |
| Market Capitalization | $86.09 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Genelux Corporation Common Stock's assets at a significant premium (4.52x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Genelux Corporation Common Stock's assets decreased by 45.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genelux Corporation Common Stock (2019–2025)
The table below shows the annual total assets of Genelux Corporation Common Stock from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $19.03 Million | -45.19% |
| 2024-12-31 | $34.72 Million | +24.46% |
| 2023-12-31 | $27.89 Million | +404.30% |
| 2022-12-31 | $5.53 Million | -31.93% |
| 2021-12-31 | $8.13 Million | -41.99% |
| 2020-12-31 | $14.01 Million | +326.94% |
| 2019-12-31 | $3.28 Million | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more